Skip to main content
Erschienen in: Journal of Clinical Immunology 5/2021

20.02.2021 | COVID-19 | Letter to Editor Zur Zeit gratis

Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia

verfasst von: Emily McKemey, Adrian M. Shields, Sian E. Faustini, Harriet J. Hill, Aliaksandra Barnskaya, Zania Stamataki, Simon Gompertz, Alex G. Richter, Davinder Dosanjh, Shyam Madathil

Erschienen in: Journal of Clinical Immunology | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Excerpt

To the Editor, …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat London J, et al. Severe COVID-19 in patients with B cell alymphocytosis and response to convalescent plasma therapy. J Clin Immunol. 2021;41(2):356–61. London J, et al. Severe COVID-19 in patients with B cell alymphocytosis and response to convalescent plasma therapy. J Clin Immunol. 2021;41(2):356–61.
2.
Zurück zum Zitat Shields AM et al. COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. J Allergy Clin Immunol. 2020;S0091–6749(20)32406-4. Shields AM et al. COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. J Allergy Clin Immunol. 2020;S0091–6749(20)32406-4.
3.
Zurück zum Zitat Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813–26.CrossRef Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813–26.CrossRef
4.
Zurück zum Zitat RECOVERY Collaborative Group et al. Dexamethasone in hospitalized patients with covid-19 - Preliminary report. N Engl J Med. 2020. RECOVERY Collaborative Group et al. Dexamethasone in hospitalized patients with covid-19 - Preliminary report. N Engl J Med. 2020.
5.
Zurück zum Zitat Simonovich VA et al. A randomized trial of convalescent plasma in covid-19 severe pneumonia. N Engl J Med 2021;384:619–29. Simonovich VA et al. A randomized trial of convalescent plasma in covid-19 severe pneumonia. N Engl J Med 2021;384:619–29.
6.
Zurück zum Zitat Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295(20):6785–97.CrossRef Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295(20):6785–97.CrossRef
7.
Zurück zum Zitat Meyts I et al. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. J Allergy Clin Immunol. 2021;147(2):520–31. Meyts I et al. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. J Allergy Clin Immunol. 2021;147(2):520–31.
8.
Zurück zum Zitat Hueso T, Pouderoux C, Péré H, Beaumont AL, Raillon LA, Ader F, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136(20):2290–5.CrossRef Hueso T, Pouderoux C, Péré H, Beaumont AL, Raillon LA, Ader F, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136(20):2290–5.CrossRef
9.
Zurück zum Zitat Jin H, et al. Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. J Allergy Clin Immunol Pract. 2020;8(10):3594–3596.e3.CrossRef Jin H, et al. Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. J Allergy Clin Immunol Pract. 2020;8(10):3594–3596.e3.CrossRef
10.
Zurück zum Zitat Buckland MS, et al. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nat Commun. 2020;11(1):6385.CrossRef Buckland MS, et al. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nat Commun. 2020;11(1):6385.CrossRef
11.
Zurück zum Zitat Van Damme KFA, et al. Case report: convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19. Front Immunol. 2020;11:596761.CrossRef Van Damme KFA, et al. Case report: convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19. Front Immunol. 2020;11:596761.CrossRef
12.
Zurück zum Zitat Schwaiger J, Karbiener M, Aberham C, Farcet MR, Kreil TR. No SARS-CoV-2 neutralization by intravenous Immunoglobulins produced from plasma collected before the 2020 pandemic. J Infect Dis. 2020;222(12):1960–4.CrossRef Schwaiger J, Karbiener M, Aberham C, Farcet MR, Kreil TR. No SARS-CoV-2 neutralization by intravenous Immunoglobulins produced from plasma collected before the 2020 pandemic. J Infect Dis. 2020;222(12):1960–4.CrossRef
13.
Zurück zum Zitat Kemp SA, et al. Neutralising antibodies in spike mediated SARS-CoV-2 adaptation. medRxiv, 2020: p. 2020.12.05.20241927. Kemp SA, et al. Neutralising antibodies in spike mediated SARS-CoV-2 adaptation. medRxiv, 2020: p. 2020.12.05.20241927.
Metadaten
Titel
Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia
verfasst von
Emily McKemey
Adrian M. Shields
Sian E. Faustini
Harriet J. Hill
Aliaksandra Barnskaya
Zania Stamataki
Simon Gompertz
Alex G. Richter
Davinder Dosanjh
Shyam Madathil
Publikationsdatum
20.02.2021
Verlag
Springer US
Schlagwort
COVID-19
Erschienen in
Journal of Clinical Immunology / Ausgabe 5/2021
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-021-00996-7

Weitere Artikel der Ausgabe 5/2021

Journal of Clinical Immunology 5/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.